Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes, Gestational | 36 | 2024 | 1263 | 6.090 |
Why?
|
Pre-Eclampsia | 39 | 2024 | 1255 | 5.700 |
Why?
|
Pregnancy Complications, Cardiovascular | 22 | 2021 | 519 | 3.180 |
Why?
|
Postpartum Period | 26 | 2024 | 1198 | 2.400 |
Why?
|
Pregnancy | 119 | 2024 | 30256 | 1.960 |
Why?
|
Hypertension | 47 | 2024 | 8616 | 1.920 |
Why?
|
Hypertension, Pregnancy-Induced | 12 | 2024 | 529 | 1.770 |
Why?
|
Cardiovascular Diseases | 23 | 2024 | 15662 | 1.280 |
Why?
|
Sodium Chloride, Dietary | 5 | 2024 | 301 | 1.170 |
Why?
|
Postmenopause | 11 | 2017 | 2518 | 1.140 |
Why?
|
Diabetes Mellitus, Type 2 | 22 | 2024 | 12252 | 1.130 |
Why?
|
Adrenal Cortex | 3 | 2012 | 134 | 1.080 |
Why?
|
Pregnancy Trimester, First | 12 | 2024 | 917 | 1.070 |
Why?
|
Aldosterone | 15 | 2023 | 881 | 1.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 9 | 2023 | 560 | 1.040 |
Why?
|
Receptor, Angiotensin, Type 1 | 3 | 2024 | 153 | 1.020 |
Why?
|
Blood Pressure | 33 | 2024 | 8543 | 0.960 |
Why?
|
Angiotensin II | 16 | 2018 | 843 | 0.960 |
Why?
|
Phthalic Acids | 6 | 2022 | 487 | 0.900 |
Why?
|
Pregnancy Proteins | 5 | 2016 | 222 | 0.840 |
Why?
|
Estradiol | 11 | 2020 | 1951 | 0.830 |
Why?
|
Reproductive History | 2 | 2015 | 210 | 0.770 |
Why?
|
Renin-Angiotensin System | 10 | 2018 | 737 | 0.770 |
Why?
|
Blood Glucose | 25 | 2024 | 6430 | 0.750 |
Why?
|
Puerperal Disorders | 5 | 2024 | 304 | 0.750 |
Why?
|
Glucose Intolerance | 4 | 2022 | 579 | 0.730 |
Why?
|
Vasomotor System | 2 | 2011 | 208 | 0.720 |
Why?
|
Female | 180 | 2024 | 397192 | 0.700 |
Why?
|
Antihypertensive Agents | 14 | 2024 | 2029 | 0.680 |
Why?
|
Renin | 11 | 2011 | 648 | 0.680 |
Why?
|
Health Promotion | 3 | 2019 | 2210 | 0.670 |
Why?
|
General Practitioners | 1 | 2021 | 103 | 0.650 |
Why?
|
Health Knowledge, Attitudes, Practice | 8 | 2023 | 4055 | 0.650 |
Why?
|
Estrogen Replacement Therapy | 10 | 2017 | 1209 | 0.650 |
Why?
|
Obstetrics | 3 | 2023 | 681 | 0.630 |
Why?
|
Women's Health | 5 | 2020 | 2082 | 0.620 |
Why?
|
Life Style | 10 | 2023 | 3932 | 0.620 |
Why?
|
Hyperaldosteronism | 5 | 2012 | 252 | 0.590 |
Why?
|
Estrogen Receptor beta | 2 | 2017 | 171 | 0.560 |
Why?
|
Risk Factors | 47 | 2024 | 74944 | 0.560 |
Why?
|
Indians, North American | 2 | 2023 | 354 | 0.540 |
Why?
|
Postnatal Care | 3 | 2024 | 273 | 0.530 |
Why?
|
Adult | 106 | 2024 | 223646 | 0.520 |
Why?
|
Pregnancy Outcome | 8 | 2024 | 2972 | 0.520 |
Why?
|
Glucose Tolerance Test | 14 | 2024 | 1183 | 0.510 |
Why?
|
Humans | 193 | 2024 | 768166 | 0.510 |
Why?
|
Metformin | 4 | 2024 | 909 | 0.500 |
Why?
|
Cardiovascular System | 2 | 2020 | 841 | 0.500 |
Why?
|
Pregnancy in Diabetics | 6 | 2024 | 198 | 0.490 |
Why?
|
Body Mass Index | 19 | 2021 | 13053 | 0.490 |
Why?
|
Weight Gain | 5 | 2018 | 2359 | 0.480 |
Why?
|
Adrenal Glands | 3 | 2012 | 557 | 0.480 |
Why?
|
Inulin | 2 | 2011 | 67 | 0.470 |
Why?
|
Adrenal Hyperplasia, Congenital | 2 | 2012 | 98 | 0.470 |
Why?
|
Menopause | 5 | 2016 | 1656 | 0.450 |
Why?
|
Education, Graduate | 2 | 2015 | 75 | 0.450 |
Why?
|
Directive Counseling | 1 | 2015 | 171 | 0.440 |
Why?
|
Insulin | 15 | 2024 | 6607 | 0.430 |
Why?
|
Saponins | 3 | 2002 | 47 | 0.420 |
Why?
|
Adrenal Insufficiency | 2 | 2012 | 195 | 0.420 |
Why?
|
Metabolic Diseases | 1 | 2019 | 684 | 0.400 |
Why?
|
Delivery, Obstetric | 3 | 2017 | 954 | 0.400 |
Why?
|
Self Report | 1 | 2024 | 3773 | 0.400 |
Why?
|
Breast Feeding | 5 | 2021 | 1363 | 0.400 |
Why?
|
Progesterone | 4 | 2007 | 752 | 0.390 |
Why?
|
Reminder Systems | 1 | 2015 | 388 | 0.390 |
Why?
|
Pregnancy Trimesters | 3 | 2018 | 197 | 0.390 |
Why?
|
Digoxin | 3 | 2002 | 246 | 0.390 |
Why?
|
Insulin Resistance | 12 | 2016 | 3986 | 0.390 |
Why?
|
Environmental Pollutants | 5 | 2022 | 1296 | 0.390 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2024 | 16045 | 0.390 |
Why?
|
Primary Prevention | 2 | 2019 | 1188 | 0.380 |
Why?
|
Glomerular Filtration Rate | 2 | 2011 | 2227 | 0.370 |
Why?
|
Medical Records | 1 | 2017 | 1410 | 0.370 |
Why?
|
Norepinephrine | 2 | 2013 | 898 | 0.370 |
Why?
|
Pregnancy Trimester, Third | 10 | 2018 | 587 | 0.370 |
Why?
|
Pregnancy Complications | 10 | 2020 | 2973 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 2 | 2015 | 3231 | 0.370 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2004 | 277 | 0.360 |
Why?
|
Pregnancy Trimester, Second | 4 | 2018 | 737 | 0.360 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 428 | 0.350 |
Why?
|
Clinical Competence | 2 | 2021 | 4858 | 0.350 |
Why?
|
Epinephrine | 2 | 2013 | 794 | 0.350 |
Why?
|
Boston | 9 | 2024 | 9374 | 0.350 |
Why?
|
Risk Reduction Behavior | 5 | 2023 | 1119 | 0.350 |
Why?
|
Calcitriol | 2 | 2007 | 303 | 0.340 |
Why?
|
Cystatin C | 1 | 2011 | 272 | 0.340 |
Why?
|
Prenatal Care | 4 | 2020 | 1162 | 0.340 |
Why?
|
Luteinizing Hormone | 1 | 2012 | 822 | 0.340 |
Why?
|
Abnormalities, Drug-Induced | 3 | 2024 | 337 | 0.340 |
Why?
|
Hypoglycemic Agents | 8 | 2024 | 3109 | 0.330 |
Why?
|
Prenatal Diagnosis | 1 | 2017 | 1275 | 0.330 |
Why?
|
Sodium | 8 | 2010 | 1597 | 0.330 |
Why?
|
Hydrocortisone | 8 | 2012 | 1841 | 0.330 |
Why?
|
Tamoxifen | 3 | 2004 | 966 | 0.330 |
Why?
|
Weight Loss | 3 | 2023 | 2721 | 0.330 |
Why?
|
Hemostasis | 1 | 2011 | 468 | 0.310 |
Why?
|
Depression, Postpartum | 1 | 2013 | 355 | 0.310 |
Why?
|
Mental Recall | 1 | 2015 | 1226 | 0.310 |
Why?
|
Behavior Therapy | 1 | 2014 | 886 | 0.310 |
Why?
|
Mentors | 4 | 2015 | 671 | 0.300 |
Why?
|
Obesity | 10 | 2023 | 13090 | 0.300 |
Why?
|
Reference Values | 12 | 2011 | 4938 | 0.300 |
Why?
|
Selective Estrogen Receptor Modulators | 3 | 2017 | 131 | 0.300 |
Why?
|
Calcium | 9 | 2007 | 5792 | 0.290 |
Why?
|
Tetrazoles | 2 | 2017 | 923 | 0.280 |
Why?
|
Follicular Phase | 2 | 2011 | 143 | 0.280 |
Why?
|
Luteal Phase | 2 | 2011 | 138 | 0.280 |
Why?
|
Menstrual Cycle | 2 | 2011 | 546 | 0.280 |
Why?
|
Calcium Channel Blockers | 4 | 2015 | 687 | 0.280 |
Why?
|
Perimenopause | 1 | 2008 | 142 | 0.270 |
Why?
|
Sodium, Dietary | 6 | 2011 | 426 | 0.270 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2012 | 735 | 0.270 |
Why?
|
Thyroid Hormones | 2 | 2017 | 407 | 0.260 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2007 | 241 | 0.260 |
Why?
|
Vasodilation | 2 | 2008 | 967 | 0.250 |
Why?
|
Young Adult | 24 | 2024 | 60066 | 0.250 |
Why?
|
Focus Groups | 4 | 2016 | 1460 | 0.250 |
Why?
|
Fetal Diseases | 3 | 2015 | 916 | 0.250 |
Why?
|
Nifedipine | 2 | 2023 | 220 | 0.240 |
Why?
|
Middle Aged | 50 | 2024 | 223492 | 0.240 |
Why?
|
Lactation | 1 | 2007 | 392 | 0.240 |
Why?
|
Population Surveillance | 1 | 2015 | 2596 | 0.240 |
Why?
|
Sex Factors | 7 | 2024 | 10632 | 0.240 |
Why?
|
Blood Pressure Determination | 3 | 2021 | 646 | 0.230 |
Why?
|
Parathyroid Hormone | 6 | 1997 | 1804 | 0.230 |
Why?
|
Biphenyl Compounds | 2 | 2017 | 1026 | 0.230 |
Why?
|
Maternal Exposure | 4 | 2024 | 1096 | 0.230 |
Why?
|
Fasting | 5 | 2021 | 1610 | 0.220 |
Why?
|
Vitamin D | 6 | 2018 | 3311 | 0.220 |
Why?
|
Patient Selection | 1 | 2016 | 4260 | 0.220 |
Why?
|
Homeostasis | 7 | 2013 | 3348 | 0.220 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2003 | 59 | 0.220 |
Why?
|
Phenols | 2 | 2018 | 526 | 0.220 |
Why?
|
Gonadal Steroid Hormones | 1 | 2007 | 707 | 0.220 |
Why?
|
Alanine Transaminase | 2 | 2016 | 606 | 0.210 |
Why?
|
Continuity of Patient Care | 1 | 2010 | 1078 | 0.210 |
Why?
|
Hyperinsulinism | 2 | 2002 | 402 | 0.200 |
Why?
|
Sodium Chloride | 1 | 2005 | 584 | 0.200 |
Why?
|
Fetal Macrosomia | 2 | 2016 | 138 | 0.200 |
Why?
|
Thyrotropin | 3 | 2008 | 834 | 0.200 |
Why?
|
Carotid Arteries | 1 | 2006 | 942 | 0.200 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 1515 | 0.200 |
Why?
|
Lipids | 6 | 2021 | 3343 | 0.190 |
Why?
|
Carotid Artery Diseases | 1 | 2008 | 879 | 0.190 |
Why?
|
Linear Models | 7 | 2021 | 5884 | 0.190 |
Why?
|
Birth Weight | 4 | 2019 | 2121 | 0.190 |
Why?
|
Adolescent | 18 | 2024 | 89169 | 0.190 |
Why?
|
Antiporters | 2 | 1993 | 276 | 0.180 |
Why?
|
Estrogens | 2 | 2020 | 1536 | 0.180 |
Why?
|
Electronic Health Records | 3 | 2021 | 4887 | 0.180 |
Why?
|
Thyroxine-Binding Proteins | 1 | 2000 | 24 | 0.180 |
Why?
|
Triglycerides | 3 | 2021 | 2464 | 0.180 |
Why?
|
Hyponatremia | 1 | 2003 | 279 | 0.180 |
Why?
|
Eclampsia | 2 | 1999 | 61 | 0.180 |
Why?
|
Congenital Abnormalities | 2 | 2017 | 703 | 0.180 |
Why?
|
Thyroid Gland | 4 | 2008 | 1171 | 0.180 |
Why?
|
Environmental Exposure | 3 | 2024 | 4543 | 0.180 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2002 | 184 | 0.180 |
Why?
|
Benzhydryl Compounds | 2 | 2018 | 944 | 0.180 |
Why?
|
Hypothyroidism | 3 | 2020 | 667 | 0.170 |
Why?
|
Estrogen Antagonists | 1 | 2000 | 151 | 0.170 |
Why?
|
Propylthiouracil | 1 | 1999 | 68 | 0.170 |
Why?
|
Enalapril | 2 | 2023 | 317 | 0.170 |
Why?
|
Gestational Age | 9 | 2021 | 3621 | 0.170 |
Why?
|
Body Weight | 4 | 2019 | 4627 | 0.170 |
Why?
|
Men's Health | 1 | 2020 | 75 | 0.170 |
Why?
|
Antithyroid Agents | 1 | 1999 | 72 | 0.170 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 317 | 0.170 |
Why?
|
Fetal Growth Retardation | 2 | 2015 | 592 | 0.160 |
Why?
|
Goiter | 1 | 1999 | 86 | 0.160 |
Why?
|
Smoking | 2 | 2018 | 9092 | 0.160 |
Why?
|
Pregnancy, High-Risk | 1 | 2020 | 121 | 0.160 |
Why?
|
Mother-Child Relations | 1 | 2023 | 498 | 0.160 |
Why?
|
Qualitative Research | 2 | 2024 | 3140 | 0.160 |
Why?
|
Cohort Studies | 13 | 2024 | 41754 | 0.150 |
Why?
|
Graves Disease | 1 | 1999 | 239 | 0.150 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2017 | 2298 | 0.150 |
Why?
|
Zona Glomerulosa | 1 | 2018 | 87 | 0.150 |
Why?
|
Health Maintenance Organizations | 1 | 2000 | 657 | 0.150 |
Why?
|
Reproduction | 2 | 2012 | 646 | 0.150 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2021 | 395 | 0.150 |
Why?
|
Internet | 5 | 2023 | 3110 | 0.150 |
Why?
|
Parity | 4 | 2012 | 931 | 0.140 |
Why?
|
Counseling | 2 | 2023 | 1554 | 0.140 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 2420 | 0.140 |
Why?
|
Odds Ratio | 8 | 2018 | 9669 | 0.140 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2000 | 399 | 0.140 |
Why?
|
Cadmium | 1 | 2018 | 217 | 0.140 |
Why?
|
Kidney | 3 | 2009 | 7064 | 0.140 |
Why?
|
Glucose | 5 | 2023 | 4352 | 0.140 |
Why?
|
Premature Birth | 3 | 2017 | 1829 | 0.140 |
Why?
|
Maternal-Fetal Exchange | 1 | 2019 | 454 | 0.140 |
Why?
|
Diet, Sodium-Restricted | 2 | 2010 | 291 | 0.130 |
Why?
|
Case-Control Studies | 12 | 2017 | 22291 | 0.130 |
Why?
|
Dietary Carbohydrates | 1 | 2021 | 896 | 0.130 |
Why?
|
Logistic Models | 7 | 2018 | 13290 | 0.130 |
Why?
|
Water-Electrolyte Balance | 3 | 2007 | 326 | 0.130 |
Why?
|
Diethylhexyl Phthalate | 1 | 2016 | 86 | 0.130 |
Why?
|
Renal Circulation | 2 | 2009 | 291 | 0.130 |
Why?
|
Yoga | 1 | 2020 | 280 | 0.130 |
Why?
|
Receptors, Mineralocorticoid | 2 | 2023 | 167 | 0.130 |
Why?
|
Infusions, Intravenous | 8 | 2010 | 2230 | 0.130 |
Why?
|
Oklahoma | 1 | 2015 | 36 | 0.120 |
Why?
|
Maternal Health Services | 1 | 2021 | 472 | 0.120 |
Why?
|
Menopause, Premature | 1 | 2016 | 124 | 0.120 |
Why?
|
Waist Circumference | 1 | 2019 | 935 | 0.120 |
Why?
|
Nitric Oxide Synthase Type III | 2 | 2016 | 706 | 0.120 |
Why?
|
Cesarean Section | 3 | 2015 | 1425 | 0.120 |
Why?
|
Pregnant Women | 4 | 2021 | 576 | 0.120 |
Why?
|
Attitude | 1 | 2020 | 771 | 0.120 |
Why?
|
Interviews as Topic | 3 | 2024 | 2741 | 0.120 |
Why?
|
Cross-Sectional Studies | 9 | 2022 | 26379 | 0.120 |
Why?
|
Bradycardia | 1 | 2016 | 305 | 0.120 |
Why?
|
NG-Nitroarginine Methyl Ester | 3 | 2016 | 262 | 0.120 |
Why?
|
Vitamin D Deficiency | 2 | 2018 | 1388 | 0.120 |
Why?
|
Diltiazem | 2 | 1998 | 132 | 0.120 |
Why?
|
Gynecology | 2 | 2023 | 534 | 0.110 |
Why?
|
Thyroiditis, Suppurative | 1 | 1994 | 7 | 0.110 |
Why?
|
Absorptiometry, Photon | 1 | 2000 | 1758 | 0.110 |
Why?
|
Algorithms | 3 | 2021 | 14164 | 0.110 |
Why?
|
Labor, Obstetric | 1 | 2017 | 323 | 0.110 |
Why?
|
Faculty, Medical | 2 | 2012 | 1226 | 0.110 |
Why?
|
Sickle Cell Trait | 1 | 1994 | 86 | 0.110 |
Why?
|
Plasminogen Activator Inhibitor 1 | 4 | 2008 | 279 | 0.110 |
Why?
|
Cardenolides | 3 | 2002 | 17 | 0.110 |
Why?
|
Male | 42 | 2024 | 364719 | 0.110 |
Why?
|
Infant, Small for Gestational Age | 2 | 2018 | 468 | 0.110 |
Why?
|
Infant, Newborn | 11 | 2024 | 26422 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2021 | 2434 | 0.110 |
Why?
|
Angiotensins | 2 | 2016 | 141 | 0.110 |
Why?
|
Lung Diseases | 2 | 2003 | 1944 | 0.110 |
Why?
|
Fluid Therapy | 1 | 2017 | 587 | 0.110 |
Why?
|
Risk Assessment | 8 | 2020 | 24315 | 0.110 |
Why?
|
Vascular Resistance | 2 | 2007 | 939 | 0.110 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 3728 | 0.110 |
Why?
|
Age Factors | 6 | 2017 | 18412 | 0.110 |
Why?
|
Prevalence | 6 | 2021 | 15869 | 0.110 |
Why?
|
Internal Medicine | 2 | 2023 | 1064 | 0.100 |
Why?
|
Retrospective Studies | 13 | 2023 | 81762 | 0.100 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2013 | 60 | 0.100 |
Why?
|
Receptors, Angiotensin | 1 | 1992 | 141 | 0.100 |
Why?
|
Fetal Blood | 2 | 2018 | 1361 | 0.100 |
Why?
|
Patient Transfer | 1 | 2019 | 792 | 0.100 |
Why?
|
Overweight | 3 | 2023 | 2448 | 0.100 |
Why?
|
Genotype | 3 | 2024 | 13045 | 0.100 |
Why?
|
Hypopituitarism | 1 | 1994 | 253 | 0.100 |
Why?
|
Blood Proteins | 2 | 1995 | 1191 | 0.100 |
Why?
|
Program Development | 3 | 2019 | 1300 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20227 | 0.100 |
Why?
|
Disabled Persons | 1 | 2021 | 1210 | 0.100 |
Why?
|
Premenopause | 2 | 2011 | 1039 | 0.100 |
Why?
|
Awareness | 2 | 2023 | 654 | 0.100 |
Why?
|
Aged | 22 | 2023 | 171504 | 0.100 |
Why?
|
Primary Health Care | 4 | 2023 | 4746 | 0.100 |
Why?
|
Steroid 21-Hydroxylase | 1 | 2011 | 33 | 0.100 |
Why?
|
Body Composition | 2 | 2012 | 2462 | 0.090 |
Why?
|
Medical History Taking | 1 | 2015 | 779 | 0.090 |
Why?
|
Sulfonylurea Compounds | 2 | 2024 | 220 | 0.090 |
Why?
|
Candidiasis | 1 | 1994 | 367 | 0.090 |
Why?
|
Cholesterol | 2 | 2005 | 2914 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1791 | 0.090 |
Why?
|
Infant, Newborn, Diseases | 1 | 2016 | 587 | 0.090 |
Why?
|
Food, Fortified | 1 | 1992 | 189 | 0.090 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5889 | 0.090 |
Why?
|
Sympathetic Nervous System | 1 | 2013 | 521 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1243 | 0.090 |
Why?
|
Propensity Score | 5 | 2017 | 1969 | 0.090 |
Why?
|
Career Choice | 3 | 2015 | 769 | 0.090 |
Why?
|
Follicle Stimulating Hormone | 1 | 2012 | 727 | 0.090 |
Why?
|
Blood Volume | 1 | 1992 | 545 | 0.090 |
Why?
|
Obstetrics and Gynecology Department, Hospital | 1 | 2010 | 41 | 0.090 |
Why?
|
Infertility | 1 | 2017 | 655 | 0.090 |
Why?
|
United States | 13 | 2024 | 73039 | 0.090 |
Why?
|
Time Factors | 9 | 2015 | 40218 | 0.090 |
Why?
|
Chronic Disease | 4 | 2017 | 9384 | 0.090 |
Why?
|
Creatinine | 3 | 2008 | 1918 | 0.090 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2020 | 2538 | 0.080 |
Why?
|
Patient Readmission | 1 | 2024 | 3288 | 0.080 |
Why?
|
Postpartum Hemorrhage | 1 | 2013 | 275 | 0.080 |
Why?
|
Preventive Health Services | 1 | 2014 | 570 | 0.080 |
Why?
|
Vitamin D-Binding Protein | 1 | 2010 | 130 | 0.080 |
Why?
|
Perinatal Mortality | 1 | 2010 | 103 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2013 | 2923 | 0.080 |
Why?
|
Central Nervous System | 1 | 2017 | 1346 | 0.080 |
Why?
|
Milk | 1 | 1992 | 438 | 0.080 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2023 | 252 | 0.080 |
Why?
|
Progesterone Congeners | 1 | 2009 | 43 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2016 | 895 | 0.080 |
Why?
|
Food | 1 | 2013 | 768 | 0.080 |
Why?
|
Professional Practice | 1 | 2011 | 314 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2013 | 682 | 0.080 |
Why?
|
Cross-Over Studies | 4 | 2004 | 2107 | 0.080 |
Why?
|
Program Evaluation | 2 | 2014 | 2507 | 0.080 |
Why?
|
Hot Flashes | 1 | 2011 | 330 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 1994 | 1622 | 0.080 |
Why?
|
Family Characteristics | 1 | 2013 | 1003 | 0.080 |
Why?
|
Vasoconstrictor Agents | 3 | 2007 | 656 | 0.080 |
Why?
|
Career Mobility | 1 | 2011 | 262 | 0.080 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5367 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2018 | 10760 | 0.080 |
Why?
|
Diet | 6 | 2021 | 8089 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2017 | 2744 | 0.070 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2009 | 118 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2496 | 0.070 |
Why?
|
Inflammation | 2 | 2005 | 10873 | 0.070 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1989 | 619 | 0.070 |
Why?
|
Systole | 1 | 2010 | 937 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 4 | 2016 | 3447 | 0.070 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2009 | 190 | 0.070 |
Why?
|
Obstetric Labor Complications | 1 | 2010 | 244 | 0.070 |
Why?
|
Bone Density | 1 | 2000 | 3573 | 0.070 |
Why?
|
Glucose Clamp Technique | 4 | 2001 | 263 | 0.070 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3858 | 0.070 |
Why?
|
Hypercholesterolemia | 2 | 2005 | 1145 | 0.070 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39348 | 0.070 |
Why?
|
Catecholamines | 1 | 2008 | 389 | 0.070 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2011 | 383 | 0.070 |
Why?
|
Infertility, Female | 1 | 2012 | 763 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2235 | 0.070 |
Why?
|
Weightlessness Simulation | 1 | 2006 | 41 | 0.070 |
Why?
|
Double-Blind Method | 6 | 2018 | 12465 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2016 | 6229 | 0.070 |
Why?
|
Lithium | 1 | 1989 | 600 | 0.070 |
Why?
|
Biomedical Research | 2 | 2020 | 3463 | 0.070 |
Why?
|
Patient Preference | 1 | 2013 | 946 | 0.060 |
Why?
|
Cytosol | 1 | 1989 | 887 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6316 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 7454 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2013 | 15454 | 0.060 |
Why?
|
Data Collection | 2 | 2012 | 3327 | 0.060 |
Why?
|
Heart Function Tests | 1 | 2006 | 317 | 0.060 |
Why?
|
Registries | 1 | 2022 | 8375 | 0.060 |
Why?
|
Students | 1 | 2015 | 1744 | 0.060 |
Why?
|
Interleukin-6 | 3 | 2023 | 3228 | 0.060 |
Why?
|
Labetalol | 2 | 2016 | 29 | 0.060 |
Why?
|
Lipoprotein-X | 1 | 2005 | 5 | 0.060 |
Why?
|
Treatment Outcome | 7 | 2023 | 65371 | 0.060 |
Why?
|
Aerospace Medicine | 1 | 2006 | 95 | 0.060 |
Why?
|
Specialization | 1 | 2010 | 779 | 0.060 |
Why?
|
Administration, Cutaneous | 2 | 2015 | 716 | 0.060 |
Why?
|
Endocrinology | 1 | 2011 | 443 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 14729 | 0.060 |
Why?
|
Cause of Death | 1 | 2015 | 3721 | 0.060 |
Why?
|
Angiotensin I | 1 | 2004 | 48 | 0.060 |
Why?
|
Fetus | 1 | 2011 | 1883 | 0.060 |
Why?
|
Prognosis | 3 | 2020 | 30010 | 0.060 |
Why?
|
Monitoring, Ambulatory | 1 | 2007 | 358 | 0.060 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2006 | 553 | 0.060 |
Why?
|
Rats, Wistar | 3 | 2018 | 1888 | 0.060 |
Why?
|
Germ-Line Mutation | 1 | 2012 | 1885 | 0.050 |
Why?
|
Nutritional Status | 1 | 2012 | 1628 | 0.050 |
Why?
|
Proteinuria | 1 | 2006 | 611 | 0.050 |
Why?
|
Perinatal Care | 1 | 2006 | 245 | 0.050 |
Why?
|
Hypotension, Orthostatic | 1 | 2006 | 258 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14783 | 0.050 |
Why?
|
Carrier Proteins | 2 | 1993 | 4937 | 0.050 |
Why?
|
Utah | 1 | 2002 | 130 | 0.050 |
Why?
|
Education, Medical | 1 | 2014 | 1742 | 0.050 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2002 | 394 | 0.050 |
Why?
|
Thyroxine | 2 | 2000 | 665 | 0.050 |
Why?
|
Osmolar Concentration | 1 | 2003 | 657 | 0.050 |
Why?
|
Urinalysis | 1 | 2005 | 370 | 0.050 |
Why?
|
Prospective Studies | 7 | 2024 | 54926 | 0.050 |
Why?
|
Seizures | 1 | 2015 | 2998 | 0.050 |
Why?
|
Maternal Welfare | 1 | 2002 | 113 | 0.050 |
Why?
|
Nuclear Family | 1 | 2023 | 311 | 0.050 |
Why?
|
Ambulatory Care Facilities | 2 | 2019 | 939 | 0.050 |
Why?
|
Australia | 1 | 2006 | 1265 | 0.050 |
Why?
|
Health Behavior | 1 | 2013 | 2650 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 1886 | 0.050 |
Why?
|
Chorionic Villi | 1 | 2002 | 53 | 0.050 |
Why?
|
Probability | 2 | 2005 | 2479 | 0.050 |
Why?
|
Liver Function Tests | 1 | 2003 | 526 | 0.050 |
Why?
|
Digitalis | 1 | 2001 | 14 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2784 | 0.050 |
Why?
|
Blood Platelets | 1 | 1992 | 2479 | 0.050 |
Why?
|
Blood Chemical Analysis | 1 | 2003 | 435 | 0.050 |
Why?
|
Bilirubin | 1 | 2003 | 438 | 0.050 |
Why?
|
Pilot Projects | 1 | 2015 | 8741 | 0.050 |
Why?
|
Plants, Toxic | 1 | 2001 | 70 | 0.050 |
Why?
|
Medicine | 1 | 2010 | 945 | 0.050 |
Why?
|
Meta-Analysis as Topic | 2 | 2017 | 1363 | 0.050 |
Why?
|
Twins, Dizygotic | 1 | 2001 | 236 | 0.050 |
Why?
|
Endocrine Disruptors | 1 | 2024 | 265 | 0.050 |
Why?
|
Mass Screening | 1 | 2017 | 5458 | 0.050 |
Why?
|
Plants, Medicinal | 1 | 2001 | 167 | 0.040 |
Why?
|
Dietary Supplements | 2 | 2018 | 3445 | 0.040 |
Why?
|
Pregnancy, Multiple | 1 | 2001 | 216 | 0.040 |
Why?
|
Incidence | 4 | 2015 | 21538 | 0.040 |
Why?
|
Trophoblasts | 1 | 2002 | 223 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3251 | 0.040 |
Why?
|
Nutrition Surveys | 2 | 2018 | 1738 | 0.040 |
Why?
|
Thyroid Function Tests | 1 | 2000 | 289 | 0.040 |
Why?
|
Twins, Monozygotic | 1 | 2001 | 472 | 0.040 |
Why?
|
Thiazolidinediones | 1 | 2003 | 461 | 0.040 |
Why?
|
Up-Regulation | 1 | 2008 | 4146 | 0.040 |
Why?
|
Hospitals, Maternity | 1 | 1999 | 31 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 1312 | 0.040 |
Why?
|
Adiponectin | 1 | 2005 | 1117 | 0.040 |
Why?
|
Angiotensinogen | 2 | 1997 | 161 | 0.040 |
Why?
|
Administration, Intravaginal | 1 | 1999 | 149 | 0.040 |
Why?
|
Enzyme Precursors | 1 | 1999 | 166 | 0.040 |
Why?
|
Magnesium Sulfate | 1 | 1999 | 73 | 0.040 |
Why?
|
Triiodothyronine | 1 | 2000 | 492 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2023 | 931 | 0.040 |
Why?
|
Isradipine | 1 | 1998 | 12 | 0.040 |
Why?
|
Phenytoin | 1 | 1999 | 189 | 0.040 |
Why?
|
Hormones | 2 | 2011 | 866 | 0.040 |
Why?
|
Child | 5 | 2023 | 80917 | 0.040 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2005 | 1656 | 0.040 |
Why?
|
Cotinine | 1 | 2018 | 206 | 0.040 |
Why?
|
Myometrium | 2 | 1998 | 174 | 0.040 |
Why?
|
Potassium | 3 | 1998 | 1315 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2018 | 12077 | 0.030 |
Why?
|
Parturition | 1 | 2021 | 455 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 1997 | 396 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2709 | 0.030 |
Why?
|
Coronary Disease | 1 | 2011 | 5919 | 0.030 |
Why?
|
Nadolol | 1 | 1996 | 29 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12543 | 0.030 |
Why?
|
Students, Medical | 1 | 2010 | 1964 | 0.030 |
Why?
|
Atenolol | 1 | 2016 | 99 | 0.030 |
Why?
|
Physicians, Primary Care | 1 | 2023 | 624 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2002 | 2357 | 0.030 |
Why?
|
Metoprolol | 1 | 2016 | 90 | 0.030 |
Why?
|
Liver Diseases | 1 | 2005 | 1305 | 0.030 |
Why?
|
Pregnancy, Animal | 1 | 2016 | 124 | 0.030 |
Why?
|
Animals | 8 | 2023 | 169246 | 0.030 |
Why?
|
Reimbursement, Incentive | 1 | 2021 | 541 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18065 | 0.030 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1998 | 480 | 0.030 |
Why?
|
Dyspnea | 1 | 2003 | 1352 | 0.030 |
Why?
|
Myocardium | 1 | 2008 | 4788 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 8054 | 0.030 |
Why?
|
Heart | 1 | 2008 | 4446 | 0.030 |
Why?
|
Thiazoles | 1 | 2003 | 1542 | 0.030 |
Why?
|
Cold Temperature | 1 | 1999 | 791 | 0.030 |
Why?
|
Ovariectomy | 2 | 2008 | 613 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2130 | 0.030 |
Why?
|
Pressoreceptors | 1 | 1994 | 99 | 0.030 |
Why?
|
Syndrome | 1 | 2001 | 3272 | 0.030 |
Why?
|
Eating | 1 | 2021 | 1542 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2004 | 2631 | 0.030 |
Why?
|
Methyldopa | 1 | 2013 | 18 | 0.030 |
Why?
|
Adrenalectomy | 1 | 1996 | 348 | 0.030 |
Why?
|
Uterine Inertia | 1 | 2013 | 29 | 0.030 |
Why?
|
Isoenzymes | 1 | 1998 | 1688 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2017 | 385 | 0.030 |
Why?
|
Albuminuria | 1 | 2017 | 658 | 0.030 |
Why?
|
Intracellular Membranes | 1 | 1994 | 388 | 0.030 |
Why?
|
Candida | 1 | 1994 | 173 | 0.030 |
Why?
|
Physicians | 1 | 2011 | 4598 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 10399 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 11879 | 0.030 |
Why?
|
Mothers | 1 | 2023 | 2209 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2002 | 2819 | 0.030 |
Why?
|
Models, Biological | 1 | 2009 | 9495 | 0.030 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 1994 | 361 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1534 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2005 | 3049 | 0.020 |
Why?
|
Fibrinolysis | 1 | 1993 | 331 | 0.020 |
Why?
|
Women, Working | 1 | 2012 | 86 | 0.020 |
Why?
|
Amniotic Fluid | 1 | 1994 | 381 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2023 | 5315 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2523 | 0.020 |
Why?
|
Vasodilator Agents | 1 | 1996 | 990 | 0.020 |
Why?
|
Rats | 3 | 2018 | 23760 | 0.020 |
Why?
|
Ergocalciferols | 1 | 1992 | 110 | 0.020 |
Why?
|
Calcifediol | 1 | 1992 | 160 | 0.020 |
Why?
|
Body Fat Distribution | 1 | 2012 | 246 | 0.020 |
Why?
|
Phenotype | 2 | 2001 | 16726 | 0.020 |
Why?
|
Prehypertension | 1 | 2011 | 63 | 0.020 |
Why?
|
Drug Combinations | 1 | 2017 | 2089 | 0.020 |
Why?
|
Placenta | 2 | 2016 | 1725 | 0.020 |
Why?
|
Teriparatide | 1 | 1992 | 226 | 0.020 |
Why?
|
Environmental Monitoring | 1 | 2017 | 1469 | 0.020 |
Why?
|
Universities | 1 | 2015 | 1005 | 0.020 |
Why?
|
Circadian Rhythm | 2 | 1993 | 2593 | 0.020 |
Why?
|
Professional Role | 1 | 2012 | 316 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2001 | 3329 | 0.020 |
Why?
|
Fura-2 | 1 | 1989 | 107 | 0.020 |
Why?
|
p-Aminohippuric Acid | 1 | 2009 | 36 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1443 | 0.020 |
Why?
|
Hypercalcemia | 1 | 1992 | 424 | 0.020 |
Why?
|
Blindness | 1 | 1993 | 587 | 0.020 |
Why?
|
Anticonvulsants | 1 | 1999 | 1923 | 0.020 |
Why?
|
Maternal Age | 1 | 2012 | 805 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2017 | 1303 | 0.020 |
Why?
|
Communication | 1 | 2023 | 3905 | 0.020 |
Why?
|
Feedback | 1 | 2012 | 799 | 0.020 |
Why?
|
Heart Defects, Congenital | 2 | 2017 | 4712 | 0.020 |
Why?
|
Lithium Carbonate | 1 | 1989 | 179 | 0.020 |
Why?
|
Benzofurans | 1 | 1989 | 138 | 0.020 |
Why?
|
Ethinyl Estradiol | 1 | 2009 | 114 | 0.020 |
Why?
|
Aging | 1 | 2007 | 8744 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 1994 | 863 | 0.020 |
Why?
|
Protein Kinase C-delta | 1 | 2008 | 115 | 0.020 |
Why?
|
Captopril | 1 | 2009 | 262 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1994 | 1493 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2003 | 13014 | 0.020 |
Why?
|
Random Allocation | 1 | 1992 | 2396 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2018 | 18349 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2862 | 0.020 |
Why?
|
Light | 1 | 1993 | 1355 | 0.020 |
Why?
|
Parathyroid Glands | 1 | 1989 | 522 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1997 | 2709 | 0.020 |
Why?
|
Cholecalciferol | 1 | 1992 | 557 | 0.020 |
Why?
|
Peer Group | 1 | 2012 | 700 | 0.020 |
Why?
|
Risk | 1 | 1999 | 9613 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2012 | 997 | 0.020 |
Why?
|
Midodrine | 1 | 2006 | 24 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6340 | 0.020 |
Why?
|
Quality Improvement | 1 | 2021 | 3857 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 1998 | 4427 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12840 | 0.020 |
Why?
|
Head-Down Tilt | 1 | 2006 | 67 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2018 | 59629 | 0.020 |
Why?
|
Signal Transduction | 3 | 2016 | 23645 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 8080 | 0.020 |
Why?
|
Liver | 2 | 2016 | 7577 | 0.020 |
Why?
|
Phosphates | 1 | 1989 | 765 | 0.020 |
Why?
|
Immobilization | 1 | 2006 | 229 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8317 | 0.020 |
Why?
|
Forecasting | 1 | 1994 | 2945 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2016 | 3139 | 0.010 |
Why?
|
Workload | 1 | 2011 | 849 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2013 | 1904 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 1560 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 1996 | 8542 | 0.010 |
Why?
|
Cattle | 1 | 1989 | 3819 | 0.010 |
Why?
|
RNA, Messenger | 3 | 2006 | 12800 | 0.010 |
Why?
|
Leadership | 1 | 2012 | 1397 | 0.010 |
Why?
|
Solubility | 1 | 2004 | 1083 | 0.010 |
Why?
|
Mice | 2 | 2023 | 82029 | 0.010 |
Why?
|
Estrogen Receptor alpha | 1 | 2006 | 581 | 0.010 |
Why?
|
Erythrocytes | 1 | 1992 | 2418 | 0.010 |
Why?
|
Models, Animal | 1 | 2008 | 2120 | 0.010 |
Why?
|
Cholestasis | 1 | 2005 | 385 | 0.010 |
Why?
|
Length of Stay | 1 | 2015 | 6498 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 1989 | 4860 | 0.010 |
Why?
|
Administration, Oral | 1 | 1989 | 4030 | 0.010 |
Why?
|
Social Support | 1 | 2011 | 2193 | 0.010 |
Why?
|
Genetic Markers | 1 | 2007 | 2603 | 0.010 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2002 | 320 | 0.010 |
Why?
|
Acute-Phase Proteins | 1 | 2001 | 252 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2008 | 2253 | 0.010 |
Why?
|
Cholesterol, HDL | 1 | 2006 | 1820 | 0.010 |
Why?
|
Medicaid | 1 | 2013 | 2840 | 0.010 |
Why?
|
Peptide Fragments | 1 | 1992 | 5151 | 0.010 |
Why?
|
Massachusetts | 1 | 2012 | 8890 | 0.010 |
Why?
|
Research Design | 1 | 2015 | 6211 | 0.010 |
Why?
|
Societies, Medical | 1 | 2011 | 3968 | 0.010 |
Why?
|
Dye Dilution Technique | 1 | 1978 | 17 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 3436 | 0.010 |
Why?
|
Thermodilution | 1 | 1978 | 50 | 0.010 |
Why?
|
Umbilical Arteries | 1 | 1998 | 77 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2002 | 1903 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2006 | 2146 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2001 | 20760 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2005 | 4833 | 0.010 |
Why?
|
Gene Expression | 1 | 2008 | 7598 | 0.010 |
Why?
|
Testosterone | 1 | 2006 | 2491 | 0.010 |
Why?
|
Cardiac Output | 1 | 1978 | 838 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2001 | 1613 | 0.010 |
Why?
|
India | 1 | 2001 | 2334 | 0.010 |
Why?
|
Infant | 1 | 2017 | 36535 | 0.010 |
Why?
|
Heart Rate | 1 | 2006 | 4214 | 0.010 |
Why?
|
Exercise | 1 | 2011 | 5955 | 0.010 |
Why?
|
Potassium Chloride | 1 | 1994 | 229 | 0.010 |
Why?
|
Posture | 1 | 1998 | 957 | 0.010 |
Why?
|
Uterine Contraction | 1 | 1994 | 91 | 0.010 |
Why?
|
Phenylephrine | 1 | 1994 | 292 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2004 | 3514 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2015 | 15832 | 0.010 |
Why?
|
Vasopressins | 1 | 1994 | 358 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1993 | 863 | 0.010 |
Why?
|
Phosphatidylcholines | 1 | 1994 | 406 | 0.010 |
Why?
|
Electrophysiology | 1 | 1994 | 1266 | 0.010 |
Why?
|
Growth Hormone | 1 | 1993 | 573 | 0.010 |
Why?
|
Coronary Thrombosis | 1 | 1993 | 440 | 0.010 |
Why?
|
Uterus | 1 | 1994 | 663 | 0.010 |
Why?
|
Oxytocin | 1 | 1994 | 404 | 0.010 |
Why?
|
Body Temperature | 1 | 1993 | 780 | 0.010 |
Why?
|
Calcium Gluconate | 1 | 1988 | 22 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 1998 | 2403 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11928 | 0.000 |
Why?
|
Metabolic Clearance Rate | 1 | 1988 | 363 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 2002 | 11095 | 0.000 |
Why?
|
Edetic Acid | 1 | 1988 | 278 | 0.000 |
Why?
|
Electrolytes | 1 | 1988 | 279 | 0.000 |
Why?
|
Melatonin | 1 | 1993 | 670 | 0.000 |
Why?
|
Tissue Plasminogen Activator | 1 | 1993 | 1165 | 0.000 |
Why?
|
Polysomnography | 1 | 1993 | 1871 | 0.000 |
Why?
|
Wakefulness | 1 | 1993 | 1284 | 0.000 |
Why?
|
Dopamine | 1 | 1993 | 1592 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1998 | 19015 | 0.000 |
Why?
|
Membrane Proteins | 1 | 1998 | 7876 | 0.000 |
Why?
|
Lung | 1 | 1994 | 10099 | 0.000 |
Why?
|
Operating Rooms | 1 | 1978 | 790 | 0.000 |
Why?
|
Intensive Care Units | 1 | 1978 | 3800 | 0.000 |
Why?
|
Cardiac Surgical Procedures | 1 | 1978 | 3683 | 0.000 |
Why?
|